ABSTRACT
Microscale thermophoresis (MST) allows for quantitative analysis of protein interactions in free solution and with low sample consumption. The technique is based on thermophoresis, the directed motion of molecules in temperature gradients. Thermophoresis is highly sensitive to all types of binding-induced changes of molecular properties, be it in size, charge, hydration shell or conformation. In an all-optical approach, an infrared laser is used for local heating, and molecule mobility in the temperature gradient is analyzed via fluorescence. In standard MST one binding partner is fluorescently labeled. However, MST can also be performed label-free by exploiting intrinsic protein UV-fluorescence. Despite the high molecular weight ratio, the interaction of small molecules and peptides with proteins is readily accessible by MST. Furthermore, MST assays are highly adaptable to fit to the diverse requirements of different biomolecules, such as membrane proteins to be stabilized in solution. The type of buffer and additives can be chosen freely. Measuring is even possible in complex bioliquids like cell lysate allowing close to in vivo conditions without sample purification. Binding modes that are quantifiable via MST include dimerization, cooperativity and competition. Thus, its flexibility in assay design qualifies MST for analysis of biomolecular interactions in complex experimental settings, which we herein demonstrate by addressing typically challenging types of binding events from various fields of life science.
Subject(s)
Proteins/chemistry , Spectrometry, Fluorescence/methods , Animals , Binding, Competitive , Dimerization , GRB2 Adaptor Protein/chemistry , Histone Methyltransferases , Histone-Lysine N-Methyltransferase/chemistry , Lasers , Molecular Conformation , Protein Binding , Protozoan Proteins/chemistry , Rats , Receptor, Adenosine A2A/chemistry , Receptors, Neurotensin/chemistry , Temperature , Thermodynamics , beta-Lactamase Inhibitors , beta-Lactamases/chemistryABSTRACT
Cruzain is a member of the papain/cathepsin L family of cysteine proteases, and the major cysteine protease of the protozoan Trypanosoma cruzi, the causative agent of Chagas disease. We report an autoinduction methodology that provides soluble cruzain in high yields (>30 mg/L in minimal medium). These increased yields provide sufficient quantities of active enzyme for use in nuclear magnetic resonance (NMR)-based ligand mapping. Using circular dichroism and NMR spectroscopy, we also examined the solution-state structural dynamics of the enzyme in complex with a covalently bound vinyl sulfone inhibitor (K777). We report the backbone amide and side chain carbon chemical shift assignments of cruzain in complex with K777. These resonance assignments were used to identify and map residues located in the substrate binding pocket, including the catalytic Cys25 and His162. Selective [(15)N]Cys, [(15)N]His, and [(13)C]Met labeling was performed to quickly assess cruzain-ligand interactions for a set of eight low-molecular weight compounds exhibiting micromolar binding or inhibition. Chemical shift perturbation mapping verified that six of the eight compounds bind to cruzain at the active site. Three different binding modes were delineated for the compounds, namely, covalent, noncovalent, and noninteracting. These results provide examples of how NMR spectroscopy can be used to screen compounds for fast evaluation of enzyme-inhibitor interactions to facilitate lead compound identification and subsequent structural studies.
Subject(s)
Cysteine Endopeptidases/chemistry , Protozoan Proteins/chemistry , Amino Acid Sequence , Catalytic Domain , Cysteine Endopeptidases/isolation & purification , Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/pharmacology , Dipeptides/pharmacology , Nuclear Magnetic Resonance, Biomolecular , Phenylalanine/analogs & derivatives , Piperazines , Protozoan Proteins/antagonists & inhibitors , Protozoan Proteins/isolation & purification , Protozoan Proteins/metabolism , Tosyl Compounds , Trypanosoma cruzi/enzymology , Vinyl Compounds/pharmacologyABSTRACT
We identified small-molecule dimer disruptors that inhibit an essential dimeric protease of human Kaposi's sarcoma-associated herpesvirus (KSHV) by screening an alpha-helical mimetic library. Next, we synthesized a second generation of low-micromolar inhibitors with improved potency and solubility. Complementary methods including size exclusion chromatography and 1H-13C HSQC titration using selectively labeled 13C-Met samples revealed that monomeric protease is enriched in the presence of inhibitor. 1H-15N HSQC titration studies mapped the inhibitor binding site to the dimer interface, and mutagenesis studies targeting this region were consistent with a mechanism where inhibitor binding prevents dimerization through the conformational selection of a dynamic intermediate. These results validate the interface of herpesvirus proteases and other similar oligomeric interactions as suitable targets for the development of small-molecule inhibitors.
Subject(s)
Herpesvirus 8, Human/drug effects , Herpesvirus 8, Human/enzymology , Protease Inhibitors/pharmacology , Protein Multimerization/drug effects , Small Molecule Libraries/pharmacology , Binding Sites , Herpesvirus 8, Human/genetics , Humans , Models, Molecular , Point Mutation , Protease Inhibitors/chemical synthesis , Protease Inhibitors/chemistry , Protein Conformation , Small Molecule Libraries/chemical synthesis , Small Molecule Libraries/chemistry , Substrate SpecificityABSTRACT
The herpesvirus proteases are an example in which allosteric regulation of an enzyme activity is achieved through the formation of quaternary structure. Here, we report a 1.7 A resolution structure of Kaposi's sarcoma-associated herpesvirus protease in complex with a hexapeptide transition state analogue that stabilizes the dimeric state of the enzyme. Extended substrate binding sites are induced upon peptide binding. In particular, 104 A2 of surface are buried in the newly formed S4 pocket when tyrosine binds at this site. The peptide inhibitor also induces a rearrangement of residues that stabilizes the oxyanion hole and the dimer interface. Concomitant with the structural changes, an increase in catalytic efficiency of the enzyme results upon extended substrate binding. A nearly 20-fold increase in kcat/KM results upon extending the peptide substrate from a tetrapeptide to a hexapeptide exclusively due to a KM effect. This suggests that the mechanism by which herpesvirus proteases achieve their high specificity is by using extended substrates to modulate both the structure and activity of the enzyme.
Subject(s)
Herpesviridae/enzymology , Peptide Hydrolases/chemistry , Peptide Hydrolases/metabolism , Binding Sites , Catalysis , Crystallography, X-Ray/methods , Enzyme Activation , Models, Biological , Models, Molecular , Protein Binding , Protein Structure, Secondary , Protein Structure, Tertiary , Substrate Specificity , Viral Proteins/chemistry , Viral Proteins/metabolismABSTRACT
The receptor associated protein (RAP) is a three domain 38kDa ER-resident chaperone that helps folding of LRP and other LDL receptor family members and prevents premature binding of protein ligands. It competes strongly with all known LRP ligands. To further understanding of the specificity of RAP-LRP interactions, the binding of RAP and RAP fragments to two domains (CR7-CR8) from one of the main ligand-binding regions of LRP has been examined by 2D HSQC NMR spectroscopy and isothermal titration calorimetry. We found that RAP contains two binding sites for CR7-CR8, with the higher affinity site (K(d) approximately 1microM) located in the C-terminal two-thirds and the weaker site (K(d) approximately 5microM) in the N-terminal third of RAP. Residues from both CR7 and CR8 are involved in binding at each RAP site. The presence of more than one binding site on RAP for CR domains from LRP, together with the previous demonstration by others that RAP can bind to CR5-CR6 with comparably low affinities suggest an explanation for the dual roles of RAP as a folding chaperone and a tight competitive inhibitor of ligand binding.
Subject(s)
Carrier Proteins/chemistry , LDL-Receptor Related Proteins/chemistry , Molecular Chaperones/chemistry , Phosphoproteins/chemistry , Protein Folding , Binding Sites , Calorimetry , Carrier Proteins/genetics , Humans , LDL-Receptor Related Proteins/genetics , Models, Molecular , Molecular Chaperones/genetics , Mutation , Nuclear Magnetic Resonance, Biomolecular , Peptide Fragments/chemistry , Phosphoproteins/genetics , Protein Binding , Protein Conformation , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , ThermodynamicsABSTRACT
The receptor associated protein (RAP) is a 38 kDa ER-resident protein that binds tightly to the low density lipoprotein receptor-related protein (LRP), and other members of the LDL receptor family of receptors, and competes with all known LRP ligands for binding to LRP. To better understand the domain structure and organization of RAP, we have expressed RAP subfragments and examined them by two-dimensional HSQC NMR and fluorescence spectroscopies, by differential scanning calorimetry, and by both equilibrium and velocity sedimentation measurements. We found that the protein is organized into three domains located in the first third (1D), middle third (2D), and last third (3D) of the protein. All three domains adopt stable tertiary structure as isolated domains and are monomers. Whereas domains 1D and 2D do not interact with one another, 3D interacts with 2D, both in a 2D-3D construct and in intact RAP. Sedimentation measurements also indicated that intact RAP, although monomeric, is significantly elongated.